#Sweden #Stockholm #share repurchase #Sobi #Incentive Program

Sobi's Strategic Share Repurchase Initiative

The Board of Directors at Swedish Orphan Biovitrum AB (Sobi®) has officially taken steps to bolster its employee retention and motivation strategies through a newly authorized share repurchase program. This decision stems from the recent Annual General Meeting on May 6, 2026, which has set the stage for crucial financial maneuvers aimed at fulfilling the company's long-term incentive objectives for its dedicated workforce.

Goals of the Repurchase Program

Under this initiative, Sobi will issue up to 223,677 redeemable and convertible class C shares. This issuance is specifically aligned with ensuring the company meets its obligations under the long-term incentive scheme designated for all permanent employees, known as the All Employee Programme. Essentially, these moves are part of Sobi’s strategic efforts to enhance employee commitment and foster a sense of ownership among staff members.

Details on Share Repurchase

The Board has granted itself the authority to embark on a comprehensive repurchase of class C shares. This program allows for one or more acquisitions until the next Annual General Meeting in 2027. The share repurchase will be conducted under a defined pricing structure, which requires shares to be repurchased at rates no lower than 100% and no higher than 105% of the share's quotient value.

On July 15, 2026, the Board signaled its intent to activate the repurchase clause based on subscription and payment by Svenska Handelsbanken AB, aiming to buy back all issued class C shares at their quota value of approximately SEK 0.55 per share. This action is expected to take place within the designated timeframe of July 16 to November 6, 2026.

Current Shareholding and Future Projections

At present, Sobi holds 10,067,297 of its common shares and has no outstanding class C shares. After the completion of the repurchase plan, all the class C shares will subsequently be transformed into common shares, bringing the total to 10,290,974 common shares. This transition is crucial as it reflects Sobi's strategy to consolidate its share structure while enabling the company to adapt to evolving market conditions and enhance its capital flexibility.

About Sobi

Sobi is a globally recognized biopharmaceutical company that is dedicated to unlocking innovative breakthroughs aimed at improving the lives of patients with rare diseases. With a robust workforce of approximately 2,000 employees spread across Europe, North America, the Middle East, Asia, and Australia, Sobi continues to drive its mission forward. In the financial year 2025, the company reported revenues amounting to SEK 28 billion, which exemplifies its strong market position. Sobi’s shares are publicly traded on Nasdaq Stockholm under the ticker symbol STOSOBI.

Stay tuned as we watch how Sobi navigates this new chapter, leveraging its commitment to employees while solidifying its standing in the competitive biopharmaceutical landscape. For further updates, follow Sobi on LinkedIn or visit their official website sobi.com.